Description:
Verucerfont is a corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC50s of ~6.1, >1000 and >1000 nM for CRF1, CRF2, and CRF-BP, respectively. Verucerfont supresses the CRH-1 receptor to decrease ACTH release following chronic stress.
Molecular Formula:
C22H26N6O2
Canonical SMILES:
CCC(C1=NC(=NO1)C)NC2=CC(=NC3=C(C(=NN23)C)C4=C(C=C(C=C4)OC)C)C
InChI:
InChI=1S/C22H26N6O2/c1-7-18(22-24-15(5)27-30-22)25-19-11-13(3)23-21-20(14(4)26-28(19)21)17-9-8-16(29-6)10-12(17)2/h8-11,18,25H,7H2,1-6H3/t18-/m0/s1
InChIKey:
VKHVAUKFLBBZFJ-SFHVURJKSA-N
Synonyms:
GSK561679; GSK 561679; GSK-561679; GSK561679A; NBI-77860; NBI 77860; NBI77860; 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine Weitere Informationen finden Sie
hier